Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Gynecologic 2Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Hemorrhage 1Sarcoma 1Prostatic Neoplasms 1Leiomyoma 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 33Paclitaxel 27Cyclophosphamide 25Carboplatin 23olaparib 21Fulvestrant 15fludarabine 14Trastuzumab 14aldesleukin 13Docetaxel 13Early Intervention, Educational 12Surveys and Questionnaires 11veliparib 10palbociclib 10Methods 10Gemcitabine 10Blood Specimen Collection 10Nivolumab 9Flow Cytometry 9Biopsy 9Bevacizumab 9sargramostim 8niraparib 7liposomal doxorubicin 7Therapeutics 7Taxes 7Standard of Care 7Psychiatric Rehabilitation 7Magnetic Resonance Spectroscopy 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Mifepristone × Gynecologic × Clear all
NCT02046421 2018-09-11

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

University of Chicago

Phase 1 Completed
31 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Breast Neoplasms, Male

NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡